Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tseng, Chi-Wei
NCT05092074: Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection	Recruiting	N/A	100	RoW	Vosevi 400/100/100 Oral Tablet	National Taiwan University Hospital	Hepatitis C Virus Infection, Treatment Side Effects, Adherence, Treatment, Effect of Drug	12/22	02/23
NCT05595733: Can NAVA Mode Reduce Mechanical Ventilation Day in Patients With COPD ?	Recruiting	N/A	50	RoW	Ventilator mode	Fu Jen Catholic University Hospital	Obstructive Lung Diseases	12/24	12/24

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tseng, Chi-Wei
NCT05092074: Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) for Patients With Hepatitis C Virus Infection	Recruiting	N/A	100	RoW	Vosevi 400/100/100 Oral Tablet	National Taiwan University Hospital	Hepatitis C Virus Infection, Treatment Side Effects, Adherence, Treatment, Effect of Drug	12/22	02/23
NCT05595733: Can NAVA Mode Reduce Mechanical Ventilation Day in Patients With COPD ?	Recruiting	N/A	50	RoW	Ventilator mode	Fu Jen Catholic University Hospital	Obstructive Lung Diseases	12/24	12/24